Teladoc, Inc. provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers of Fortune 1000 companies, health plans, health systems, and other entities. Teladoc, Inc. was founded in 2002 and is headquartered in Purchase, New York.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TDOC
CUSIPN/A
Phone203-635-2002
Debt
Debt-to-Equity Ratio0.58
Current Ratio3.14
Quick Ratio3.14
Price-To-Earnings
Trailing P/E Ratio-45.76
Forward P/E Ratio-50.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$233.28 million
Price / Sales22.45
Cash FlowN/A
Price / CashN/A
Book Value$9.80 per share
Price / Book7.68
Profitability
EPS (Most Recent Fiscal Year)($1.65)
Net Income$-106,780,000.00
Net Margins-37.78%
Return on Equity-19.10%
Return on Assets-11.57%
Miscellaneous
Employees1,231
Outstanding Shares69,540,000
Market Cap$5.14 billion
Teladoc (NYSE:TDOC) Frequently Asked Questions
What is Teladoc's stock symbol?
Teladoc trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."
How were Teladoc's earnings last quarter?
Teladoc Inc (NYSE:TDOC) announced its earnings results on Wednesday, August, 1st. The health services provider reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.01. The health services provider had revenue of $94.60 million for the quarter, compared to analyst estimates of $91.56 million. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The company's revenue for the quarter was up 112.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.28) earnings per share. View Teladoc's Earnings History.
When is Teladoc's next earnings date?
What price target have analysts set for TDOC?
19 analysts have issued 1-year price objectives for Teladoc's stock. Their forecasts range from $39.00 to $90.00. On average, they expect Teladoc's stock price to reach $65.6842 in the next twelve months. This suggests that the stock has a possible downside of 12.9%. View Analyst Price Targets for Teladoc.
What is the consensus analysts' recommendation for Teladoc?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teladoc.
What are Wall Street analysts saying about Teladoc stock?
Here are some recent quotes from research analysts about Teladoc stock:
- 1. Canaccord Genuity analysts commented, "We remain confident in our above-consensus estimate (~22k) for Q2 unit sales, as web traffic trends and used car market strength suggest CVNA continues to generate healthy gains in consumer mindshare. Moreover, third-party data (including transactional inputs from DataWeave) imply unit sales above consensus and our estimates. While Q3 guidance is somewhat of a wildcard (early signals are positive) we continue to like shares at current levels. Reiterate Outperform rating." (8/2/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on TDOC shares and raise our 12-month price target to $52 from $50. On August 1, TDOC reported 2Q18 results. Revenue was above our estimate and FactSet consensus. Adjusted EBITDA was ahead of consensus expectations as well. The company raised its 2018 guidance to reflect the acquisition of Advance Medical, recognizing the TRICARE launch is slightly delayed. Revenue grew 112%, or 39% organically. We continue to believe that TDOC is positioned to benefit from solid telehealth growth, but that the shares’ current valuation already reflects the strong growth potential." (8/1/2018)
- 3. According to Zacks Investment Research, "The stock of Teladoc has outperformed the industry year to date. The company is witnessing steady business growth with insurers and customers increasingly embracing telehealth. It’s organic growth initiative remains on track. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. Also the company boasts an impressive clientele. The company has also provided strong guidance for 2017. The company has incurred significant losses in each period since its inception in 2002. Teladoc has been unable to generate cash from operations and we have doubts over its ability to do so in the coming quarters. Its high debt level has caused a spike in interest expense which has dented its operating margins." (10/18/2017)
Are investors shorting Teladoc?
Teladoc saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 18,307,585 shares, a drop of 1.9% from the July 13th total of 18,654,760 shares. Based on an average daily trading volume, of 1,775,313 shares, the days-to-cover ratio is presently 10.3 days. Approximately 33.7% of the shares of the stock are sold short. View Teladoc's Current Options Chain.
Who are some of Teladoc's key competitors?
Some companies that are related to Teladoc include Mylan (MYL), TERUMO Corp/ADR (TRUMY), AmerisourceBergen (ABC), Laboratory Corp. of America (LH), BioMarin Pharmaceutical (BMRN), SYSMEX Corp/ADR (SSMXY), UCB (UCBJF), Cardinal Health (CAH), ABIOMED (ABMD), Smith & Nephew (SNN), UCB S A/ADR (UCBJY), ResMed (RMD), Quest Diagnostics (DGX), Sino Biopharmaceutical (SBMFF) and Incyte (INCY).
Who are Teladoc's key executives?
Teladoc's management team includes the folowing people:
- Mr. Jason Nathanial Gorevic, CEO & Director (Age 46)
- Mr. Peter A. McClennen, Pres (Age 49)
- Mr. Mark J. Hirschhorn, Exec. VP, COO & CFO (Age 53)
- Mr. Adam Christian Vandervoort, Chief Legal Officer & Sec. (Age 43)
- Dr. Lewis Levy M.D., FACP, Chief Medical Officer (Age 59)
When did Teladoc IPO?
(TDOC) raised $112 million in an IPO on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Has Teladoc been receiving favorable news coverage?
Media stories about TDOC stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Teladoc earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news coverage about the health services provider an impact score of 46.38 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Teladoc.
Who are Teladoc's major shareholders?
Teladoc's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (12.51%), BlackRock Inc. (7.65%), Eagle Asset Management Inc. (2.89%), Bank of America Corp DE (2.71%), Janus Henderson Group PLC (2.55%) and Zevenbergen Capital Investments LLC (2.34%). Company insiders that own Teladoc stock include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Lewis Levy, Lp Chp III, Mark Hirschhorn, Michael Goldstein, Michael H King, Peter A Mcclennen and Trident Capital Fund Vi Lp. View Institutional Ownership Trends for Teladoc.
Which major investors are selling Teladoc stock?
TDOC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Global Thematic Partners LLC, Jennison Associates LLC, Eagle Asset Management Inc., Waddell & Reed Financial Inc., Carillon Tower Advisers Inc., Granahan Investment Management Inc. MA and Peregrine Capital Management LLC. Company insiders that have sold Teladoc company stock in the last year include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Lewis Levy, Mark Hirschhorn, Michael Goldstein and Peter A Mcclennen. View Insider Buying and Selling for Teladoc.
Which major investors are buying Teladoc stock?
TDOC stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Summit Partners L P, Westwood Management Corp IL, BlackRock Inc., OppenheimerFunds Inc., Artisan Partners Limited Partnership, Strs Ohio and Motley Fool Wealth Management LLC. View Insider Buying and Selling for Teladoc.
How do I buy shares of Teladoc?
Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teladoc's stock price today?
One share of TDOC stock can currently be purchased for approximately $75.40.
How big of a company is Teladoc?
Teladoc has a market capitalization of $5.14 billion and generates $233.28 million in revenue each year. The health services provider earns $-106,780,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Teladoc employs 1,231 workers across the globe.
How can I contact Teladoc?
Teladoc's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]
MarketBeat Community Rating for Teladoc (NYSE TDOC)
MarketBeat's community ratings are surveys of what our community members think about Teladoc and other stocks. Vote "Outperform" if you believe TDOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
